New cholesterol drug could prevent thousands of heart attacks, study suggests
NCT ID NCT07214857
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used national health survey data to estimate how many US adults with high cholesterol might be eligible for a new drug called inclisiran. Researchers also calculated how many heart attacks and strokes could be prevented over 10 years if these patients took the drug. The study did not give inclisiran to anyone—it was a computer-based analysis using existing health records.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inclisiran
What this could lead to
If the estimates are accurate, this could show that inclisiran might prevent thousands of heart attacks and strokes in eligible patients.
What could go wrong
This is a modeling study based on surveys, not a clinical trial testing the drug directly. Real-world results may differ, and inclisiran's actual effectiveness and safety are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States